Haisco Pharmaceutical Group Co., Ltd.
002653
Κατάταξη σε μετοχές
#2010
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Τιμή μετοχής
$9.03
Κεφαλαιοποίηση
$10.30B
Αλλαγή (1 ημέρα)
4.55%
Αλλαγή (1 έτος)
24.15%
Χώρα
CN
Εμπόριο Haisco Pharmaceutical Group Co., Ltd. (002653)
Κατηγορία
Healthcare
Κέρδη για την Haisco Pharmaceutical Group Co., Ltd. (002653)
Κέρδη τον Jun 2026 TTM: $144.70M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Haisco Pharmaceutical Group Co., Ltd., τα τρέχοντα κέρδη της εταιρείας είναι $144.70M. Το 2023, η εταιρεία παρουσίασε κέρδη $42.74M, μείωση σε σύγκριση με των κερδών του 2022 που ήταν $53.15M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Haisco Pharmaceutical Group Co., Ltd. από 2008 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $144.70M | 128.15% |
| 2024 | $63.43M | 48.41% |
| 2023 | $42.74M | -19.59% |
| 2022 | $53.15M | -33.86% |
| 2021 | $80.36M | -23.86% |
| 2020 | $105.54M | 34.49% |
| 2019 | $78.47M | 67.09% |
| 2018 | $46.96M | 18.07% |
| 2017 | $39.78M | -42.90% |
| 2016 | $69.65M | 8.93% |
| 2015 | $63.94M | -21.50% |
| 2014 | $81.46M | -13.14% |
| 2013 | $93.78M | 21.75% |
| 2012 | $77.03M | 31.46% |
| 2011 | $58.59M | 6.29% |
| 2010 | $55.13M | 19.25% |
| 2009 | $46.23M | 45.27% |
| 2008 | $31.82M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | 3,545.32% |
US
|
|
| $-3.09B | -2,233.33% |
US
|
|
| $-4.02B | -2,875.47% |
AU
|
|
| $1.95B | 1,248.04% |
NL
|
|
| - | - |
CH
|
